Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Saved in:
| Title: | Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. |
|---|---|
| Authors: | Lang JE; University of Southern California, Los Angeles, USA. LANGJ2@ccf.org., Forero-Torres A; University of Alabama at Birmingham, Birmingham, USA., Yee D; University of Minnesota, Minneapolis, USA., Yau C; University of California San Francisco, San Francisco, USA., Wolf D; University of California San Francisco, San Francisco, USA., Park J; University of California San Francisco, San Francisco, USA., Parker BA; University of California San Diego, San Diego, USA., Chien AJ; University of California San Francisco, San Francisco, USA., Wallace AM; University of California San Francisco, San Francisco, USA., Murthy R; University of Texas MD Anderson Cancer Center, Houston, USA., Albain KS; Loyola University Chicago Stritch School of Medicine, Maywood, USA., Ellis ED; Swedish Cancer Institute, Seattle, USA., Beckwith H; University of Minnesota, Minneapolis, USA., Haley BB; University of Texas Southwestern, Dallas, USA., Elias AD; University of Colorado, Boulder, USA., Boughey JC; Mayo Clinic Rochester, Rochester, USA., Yung RL; University of Washington, Seattle, USA., Isaacs C; University of Georgetown, Washington, DC, USA., Clark AS; University of Pennsylvania, Philadelphia, USA., Han HS; Moffitt Cancer Center, Tampa, USA., Nanda R; University of Chicago, Chicago, USA., Khan QJ; University of Kansas, Lawrence, USA., Edmiston KK; Inova Health System, Virginia, USA., Stringer-Reasor E; University of Alabama at Birmingham, Birmingham, USA., Price E; University of California San Francisco, San Francisco, USA., Joe B; University of California San Francisco, San Francisco, USA., Liu MC; Mayo Clinic Rochester, Rochester, USA., Brown-Swigart L; University of California San Francisco, San Francisco, USA., Petricoin EF; George Mason University, Fairfax, USA., Wulfkuhle JD; George Mason University, Fairfax, USA., Buxton M; University of California San Francisco, San Francisco, USA., Clennell JL; University of California San Francisco, San Francisco, USA., Sanil A; Berry Consultants, LLC, Austin, USA., Berry S; Berry Consultants, LLC, Austin, USA., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, USA., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, USA., Hirst GL; University of California San Francisco, San Francisco, USA., Singhrao R; University of California San Francisco, San Francisco, USA., Asare AL; Quantum Leap Healthcare Collaborative, San Francisco, USA., Matthews JB; University of California San Francisco, San Francisco, USA., Melisko M; University of California San Francisco, San Francisco, USA., Perlmutter J; Gemini Group, Michigan, USA., Rugo HS; University of California San Francisco, San Francisco, USA., Symmans WF; University of Texas MD Anderson Cancer Center, Houston, USA., van 't Veer LJ; University of California San Francisco, San Francisco, USA., Hylton NM; University of California San Francisco, San Francisco, USA., DeMichele AM; University of Pennsylvania, Philadelphia, USA., Berry DA; Berry Consultants, LLC, Austin, USA., Esserman LJ; University of California San Francisco, San Francisco, USA. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2022 Dec 01; Vol. 8 (1), pp. 128. Date of Electronic Publication: 2022 Dec 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-022-00493-z |
